RE
LAB icon

RBC Europe’s Standard BioTools LAB Stock Holding History

RBC Europe’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-172
Closed -$1.13K – 900
2021
Q3 		$1.13K Hold
172
– – ﹤0.01% 1174
2021
Q2 		$1.06K Hold
172
– – ﹤0.01% 1170
2021
Q1 		$777 Hold
172
– – ﹤0.01% 1130
2020
Q4 		$1.03K Hold
172
– – ﹤0.01% 1088
2020
Q3 		$1.28K Buy
+172
New +$1.19K ﹤0.01% 1006

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RBC Europe's LAB Position: Q4 2021 in Review

RBC Europe sold out of Standard BioTools (LAB) in Q4 2021, closing a stake of 172 shares — an estimated $1.13K sold.

RBC Europe first reported a position in LAB in Q3 2020 and held it in 5 quarters. The position peaked at $1.28K in Q3 2020. 121 funds tracked by Wall St. Rank hold LAB as of Q4 2021.

  • RBC Europe reported no remaining Standard BioTools position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 172 Standard BioTools shares in Q4 2021, an estimated $1.13K.
  • RBC Europe first reported a position in Standard BioTools in Q3 2020 and held it in 5 quarters.
  • RBC Europe's Standard BioTools position peaked at $1.28K in Q3 2020.
  • 121 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.